Aclarion Secures Key Patent for Nociscan's MR Spectroscopy Scan Accuracy
Event summary
- Aclarion received a Notice of Allowance from the USPTO for a patent titled 'Multi-Voxel Prescription for Lumbar Disc Evaluation' on August 12, 2026.
- The patent improves the precision of MRS data capture within lumbar discs, reducing scan time and enhancing reproducibility across imaging centers.
- This extends Aclarion's IP portfolio to over 65 issued and pending patents worldwide.
- Nociscan demonstrates a 97% surgical success rate when all Nociscan-positive discs are treated.
The big picture
Aclarion's latest patent fortifies its position in the chronic low back pain diagnostics market, where precise non-invasive solutions are increasingly critical. With over 266 million people globally suffering from degenerative spine disease, the company's ability to enhance scan accuracy and reproducibility could drive broader adoption of Nociscan. This move aligns with the industry trend toward AI-augmented diagnostic tools that improve treatment outcomes.
What we're watching
- Adoption Dynamics
- How the patent will accelerate Nociscan's adoption across imaging centers by reducing variability in scan results.
- Competitive Moat
- Whether Aclarion can sustain its lead in MR Spectroscopy diagnostics with this strengthened IP portfolio.
- Technological Integration
- The pace at which Aclarion integrates this innovation into existing MRI workflows and trains technologists.
Related topics